China News Service, January 15th. On January 15, the well-known medical artificial intelligence company Yidu Technology was officially listed on the main board of the Hong Kong Stock Exchange with the stock code 2158.HK.
According to an announcement by the Hong Kong Stock Exchange, the price of the Yidu Technology Development Company is set at 26.30 Hong Kong dollars per share, with 100 shares per lot.
If the over-allotment option is not exercised, the net proceeds from the global offering will be approximately HK$3.9 billion.
Yidu Technology opened higher on its first day of listing, and its market value exceeded HK$57 billion at one time.
As of press time, Yidu Technology's share price has risen by 136.5% to 62.20 Hong Kong dollars, and the current total market value is about 56.1 billion Hong Kong dollars.
The core management of Yidu Technology toasted at the listing ceremony
At the offline listing ceremony held in Beijing, the group’s core management representatives, shareholder representatives, and partner representatives jointly sounded the gong for Yidu Technology’s Hong Kong listing.
"The listing is an important milestone in the development of Yidu Technology. In the future, Yidu Technology will continue to uphold the original intention of'green medical', invest in research and development, insist on innovation, and contribute its own strength to the development of'Healthy China 2030' and medical and health technology. "Zhang Shi, senior vice president and head of government affairs of Yidu Technology Group, said.
The gong knocking ceremony site of Yidu Technology's listing
Relevant shareholder representatives stated in the on-site speech that medical care is closely related to people’s livelihood, and companies in this field need to have long-term strategic vision and continuous innovation capabilities. Since its establishment, Yidu Technology has focused on the long-term and invested a lot of human and material resources in technology. Efforts to break through the pain points of the intelligentization of the medical industry, and develop its own "medical brain".
In his view, Yidu Technology, which adheres to long-termism and strives to lay the foundation for the development of intelligent medical care, is the real backbone of the industry.
Listing is a new starting point for the development of an enterprise, and it is believed that Yidu Technology, which has a profound technical accumulation, has a bright future.
Shareholder representative Bai Xiaoqing, Director of Private Equity of CIC International, delivered a speech at the listing ceremony
Policy and technology dual support market and revenue breakthrough
The "Healthy China" national strategy and the "Healthy China 2030" planning outline sounded the charge of building a healthy China.
"Healthy China" is one of the long-term goals of basically achieving socialist modernization by 2035.
Emerging technologies represented by cloud computing, big data, and artificial intelligence have become the starting point for the implementation of the "Healthy China" strategy, providing strong support for its development.
Founded in 2014, Yidu Technology provides medical solutions based on artificial intelligence and big data technology to major participants in the medical industry, including hospitals, pharmaceuticals, biotechnology and medical equipment companies, research institutions, insurance companies, doctors and Patients, as well as regulators and policy makers provide services and cooperate with them.
At the beginning of its establishment, Yidu Technology directly attacked the pain points of the industry, hoping to use technology to improve medical efficiency, reduce costs, and create a new type of "green medical care", that is, to make medical care more accessible, accurate, and value-oriented, and benefit more ordinary people.
The premise of artificial intelligence empowering medical care is high-quality medical health data.
The "People's Daily" once stated that my country has a population of nearly 1.4 billion and tens of thousands of hospitals, and the scale of medical and health data generated every year is huge, but most of them are unstructured data, which has become a bottleneck for medical research and innovation.
The "YiduCore" independently developed by Yidu Technology can conduct in-depth processing and analysis of authorized large-scale multi-source heterogeneous medical data, establish real-world disease domain models, and help medical research, medical management, government public decision-making, innovative drug research and development, Help patients realize intelligent disease management.
This has also laid a solid foundation for the long-term development of Yidu Technology.
With "YiduCore", Yidu Technology can provide key players in the medical industry with data-driven intelligent solutions, thereby gradually forming its own diversified business structure.
Up to now, Yidu Technology has formed three major business segments: big data platforms and solutions, life science solutions, and health management platforms and solutions.
The number of customers in the three major sectors has increased year by year.
As of June 30, 2020, the number of active customers for big data platforms and solutions, and life science solutions were 87 and 86 respectively, compared with 62 and 47 in the same period last year.
The prospectus shows that from the 2018 fiscal year to the 2020 fiscal year, Yidu Technology recorded total revenue of 22.727 million yuan, 102 million yuan and 558 million yuan, respectively, and the growth rate in the past three years reached 348.9% and 447.1% respectively.
Yidu Technology has achieved both market and revenue breakthroughs.
Among them, the big data platform and solution business achieved a compound growth rate of 176.11% in three years, from 17.672 million yuan in fiscal year 2018 to 372 million yuan in fiscal year 2020.
Life science solutions revenue increased from 5.055 million yuan in fiscal year 2018 to 103 million yuan in fiscal year 2020, with a compound growth rate of 173.13%.
The health management platform and solutions business increased from 10.758 million yuan in fiscal year 2019 to 55.648 million yuan in fiscal year 2020, an increase of 417.27% year-on-year.
Help local governments fight the epidemic with long-term mission as their responsibility
The dual blessing of policy and technology has pushed Yidu Technology onto the fast track of development. With the further enhancement of its own strength and continuous investment in research and development, Yidu Technology has gradually widened the boundaries and promoted the development of the health industry more effectively.
In the face of the epidemic, Yidu Technology responded quickly and launched an urban immunization platform in time to help dynamically control the epidemic and restore the economy.
In Wuhan, the front line of the outbreak, Yidu Technology dispatched an "anti-epidemic team" to reverse the situation, using the advantages of medical artificial intelligence technology to cooperate with Wuhan Tongji Hospital to build a new crown pneumonia specific disease big data intelligent platform, and provide Wuhan Tongji Hospital with new crown pneumonia. Provide strong support and help for the diagnosis, treatment and scientific research work of Wuhan to help improve Wuhan’s “urban immunity”.
In Ningbo, Yidu Technology promptly established the "Ningbo Epidemic Response Action Team" to use artificial intelligence technology to predict the development of the Ningbo epidemic, and also assisted the Chinese Center for Disease Control and Prevention to continue to publish the "Overseas New Coronary Pneumonia Import Risk Assessment Report".
In Beijing, Yidu Technology uses artificial intelligence technology to help the Center for Disease Control and Prevention to efficiently track the source of the epidemic in Shunyi District.
At present, many Yidu Technology employees are fighting on the front line of the anti-epidemic battlefield such as Hebei.
In terms of improving the efficiency of medical services, accelerating the construction of the public health system, and assisting in the fight against the epidemic, the technical value of Yidu Technology has been continuously released.
At the same time, Yidu Technology is also constantly playing a role in protecting people with low immunity.
With the aging of the population, the risk of becoming poverty due to illness and returning to poverty due to illness is magnified, and the importance of health insurance and health management oriented toward "equal protection" has become more prominent.
Factor Health, a subsidiary of Yidu Technology, actively participates in the "Human Insurance" project, helping many insurance companies to provide supplementary medical insurance protection for the general public, and reduce the incidence of diseases for the people with good health management solutions.
The inclusive supplementary medical insurance "Beijing Jinghuibao", which is participated and promoted by FactorHealth, was launched in October 2020; the "Yuhuibao" launched in Chongqing, a municipality directly under the central government in the southwest, is also well received by the public.
At present, the level of technological innovation in the field of health and health has become an important indicator of the level of technological innovation in a country.
As the National Development and Reform Commission clearly included artificial intelligence in the new infrastructure category in April 2020, the market's demand for AI has greatly increased.
Under the wave of new infrastructure construction, Yidu Technology is expected to accelerate the construction of new medical infrastructure by virtue of its core AI technology capabilities such as "YiduCore", and continue to help "Healthy China" continue to move forward.
The listing is just a new starting point for Yidu Technology.
Gong Rujing, the founder and chairman of Yidu Technology, said that in order to allow the company’s business to focus on the mission of the group for a long time in the future, and to make value-oriented precision medicine benefit everyone, she has signed a lock-up document and promised Most of the company's shares held are locked up for ten years.
"Medical is a long-term track. I am determined to use our motivation and actions to be friends of time with everyone."